The IBD community came together virtually Jan. 21-24, 2021, for the annual Crohn’s & Colitis Congress®, a partnership of AGA and the Crohn’s & Colitis Foundation. Thanks to our engaged attendees and expert faculty, the meeting was a huge success! Our more than 1,400 attendees left with state-of-the-art updates to improve IBD patient care and research. Below are five of the top take-aways from the meeting, as seen on Twitter.
Save the date: next year’s Congress will take place in Las Vegas, Jan. 20-22, 2022.
There is emerging understanding of possible role for diet as complementary to conventional therapies in #Crohns (sorry not UC yet). This is seen with exclusion-type diets, like the study in kids by Dr. A Levine, also presented today: https://t.co/ORpAk2uqNP #CCCongress21 pic.twitter.com/Z2pqPMZGtb— David T. Rubin, MD (@IBDMD) January 22, 2021
#CCCongress21 #IBD A to Z @UmaMahadevanIBD— Aline Charabaty, M.D. (@DCharabaty) January 24, 2021
Risks/Benefits of #IBD Rx
🔺Steroids often seen « acceptable » but have ⬆️⬆️ SE
🔺5ASA are safe but ineffective in CD —> Put pt at ⬆️ Risk of dis. progression & complications
🔺AZA/6MP are not safer than biologics pic.twitter.com/Bs7lIMOpO2
This is a fantastic set of slides of the most common primary ocular EIMs in #IBD! Diagnosis, Treatment, and when to 📞 the Opthalmologist! 👁 🔥 #CCCongress21 #IBDAtoZ @SophieBalzoraMD pic.twitter.com/NPDadcWsuC— Joshua M. Steinberg, MD (@joshsteinbergMD) January 24, 2021
Hot topic with #IBD patients: "When can I stop my therapy?"— Jami Kinnucan MD (@ibdgijami) January 21, 2021
Answer: We should address at each visit if appropriate for de-escalation (not discontinuation) of medical therapy. @IBDMD great talk #CCCongress21 about when is it appropriate to consider reducing therapy in IBD pic.twitter.com/HzFh7BZpyb